Staff editor
Elisabetta Caselli, University of Ferrara (Italy), talks about a new and innovative use of probiotics to modulate the "hospital microbiome” in order to reduce the use of chemical disinfectants.
George Paraskevakos, Executive Director at International Probiotics Association, talks about probiotic and live biotherapeutic products market evolution and perspective.
The highlights of the Postbiotics Discussion Panel that took place in Bratislava during IPC 2023.
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis.
Philippe Langella, Research Director at the French National Institute of Agricultural Research, discussed the potential of Faecalibacterium Prausnitzii as Live Biotherapeutics for several disease.
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x.
MAP 315, is a novel live biotherapeutic product being developed for the treatment of ulcerative colitis and was discovered and developed using Microba’s data-driven Therapeutics Platform.
Together with Professor Lorenzo Morelli we focused on the significant role of diet and the microbiome in terms of health benefits, food production, and agri-industry systems.
Biofarma Group's R&D to support people in the pre-depressive phase.
Ensemble No.3 (ENS-003) is in development to address vulvovaginal candidiasis – a vaginal yeast infection for which antifungal treatments offer limited protection from recurrence.
